Expert Video - How do doctors tell de novo AML, AML-MRC, and tAML apart?

Dr. David Steensma, an expert on acute myeloid leukemia (AML), explains that your medical history and cells from a bone marrow biopsy help doctors tell types of AML apart. Chemotherapy or radiation in the last 10 years indicates treatment-related AML (tAML), especially if there is a certain genetic pattern. AML with myelodysplasia-related changes (AML-MRC) has certain cell changes that can be seen under a microscope. Without these changes or prior treatment, it is likely de novo AML. People with de novo AML also tend to have higher white blood cell counts.

  • Share with family and friends:

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about AML which will help other patients, caregivers and families.

Please rate this content:

This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.

This activity is supported by educational grants from AbbVie, Celgene Corporation, Daiichi Sankyo, Jazz Pharmaceuticals and Takeda Oncology.

This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.